<DOC>
	<DOCNO>NCT00665951</DOCNO>
	<brief_summary>This pilot pharmacokinetic study design exclude large difference ( &gt; 40 % ) pharmacokinetics ( esp . AUC ) two new Lopimune formulation brand formulation . The formal bioequivalence study adequate power conduct manufacturer . In order get data independently manufacturer information earlier phase , small pilot study initiate . The initial study show decline bioavailability granule fast condition . The study extend arm determining pharmacokinetics granule food ( compare oral solution take food ) .</brief_summary>
	<brief_title>Pharmacokinetic Study Two Generic co-Formulations Lopinavir/Ritonavir HIV Infected Children ( SURF )</brief_title>
	<detailed_description>Cipla develop two co-formulated form lopinavir/ritonavir second-line antiretroviral therapy child : Lopimune granule Lopimune tablet . They contain 100mg lopinavir 25mg ritonavir . Primary objective study : To determine pharmacokinetic profile lopinavir ritonavir two different co-formulations ( Lopimune granules Lopimune tablet ) single-dose HIV-negative , healthy adult subject , compare brand product . Secondary objective : To evaluate safety single-dose administration two generic co-formulations lopinavir/ritonavir compare brand product .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Subject least 18 old 55 year age day first dose . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior first dose . Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . Subject able willing sign Informed Consent Form prior screen evaluation . Subject good age appropriate health condition Subject normal blood pressure pulse rate , accord investigator 's judgment . Female subject either childbearing potential , childbearing potential practice one follow method birth control : condom , sponge , foam , jelly , diaphragm copper intrauterine device ( IUD ) ; vasectomize partner ; total abstinence sexual intercourse . Documented history sensitivity/idiosyncrasy medicinal product excipients . Positive HIV test . Positive hepatitis B C test . Therapy drug , include oral contraceptive . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , gastrointestinal disorder , renal hepatic disorder , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . History current abuse drug , alcohol solvent . Inability understand nature extent trial procedure require . Participation drug trial within 60 day prior first dose . Donation blood within 60 day prior first dose . Febrile illness within 3 day first dose . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>pediatric</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>HIV infection</keyword>
</DOC>